INTC:NASDAQIntel Corporation Analysis
Data as of 2026-05-25 - not real-time
$119.84
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Intel (INTC) has staged a spectacular rally in 2026, with the stock up more than 220% YTD and trading near $120, well above its DCF‑derived fair value of roughly $22. Technical momentum is strong: the 20‑day SMA (~$109) sits comfortably below the current price, the 50‑day SMA (~$76) and 200‑day SMA (~$47) are all far beneath, and the trend direction is flagged as bullish. However, the RSI sits at 68, edging into overbought territory, and the MACD histogram is negative with a bearish signal line, hinting at possible short‑term weakness. Fundamentally, the picture is mixed: revenue growth is modest at 7.2%, but profit margin is negative (‑5.9%) and free cash flow remains deeply negative, while debt‑to‑equity is an elevated 36× and forward P/E is 77 versus an industry average of 39. Recent news of a preliminary Apple chip deal and talks with SK Hynix have reignited confidence in the foundry segment, yet the valuation gap and high beta (≈2.4) keep risk levels elevated. Overall, the stock is riding a wave of optimism that may be outpacing underlying earnings reality, suggesting caution despite the headline‑grabbing gains.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Recent Apple chip partnership boosting market sentiment
- Bullish SMA alignment but RSI approaching overbought
- Bearish MACD signal indicating possible near‑term pullback
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Continued product launches (Core Ultra) and foundry expansion
- Persistently negative free cash flow and high leverage
- Valuation still far above DCF fair value and sector peers
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Negative profit margins and ROE indicating earnings weakness
- DCF fair value suggests a downside of over 25% from current price
- High beta and volatility expose the stock to market swings
Key Metrics & Analysis
Financial Health
Revenue Growth7.20%
Profit Margin-5.90%
P/E Ratio77.8
ROE-2.91%
ROA0.63%
Debt/Equity36.03
P/B Ratio5.4
Op. Cash Flow$10.0B
Free Cash Flow$-8301250048
Industry P/E39.5
Technical Analysis
TrendBullish
RSI68.2
Support$80.80
Resistance$132.75
MA 20$109.06
MA 50$76.45
MA 200$47.17
MACDBearish
VolumeDecreasing
Fear & Greed Index91.8
Valuation
Fair Value$22.14
Target Price$87.86
Upside/Downside-26.68%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.40
Volatility97.44%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.